News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 [Seeking Alpha]

Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration

Altimmune (NASDAQ:ALT) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.

11/6/2025

07:00 am

alt

4.2%

BEAT

8/12/2025

07:00 am

alt

2.9%

BEAT

5/13/2025

07:00 am

alt

-3.7%

BEAT

2/27/2025

07:00 am

alt

5.8%

BEAT

Form 4 Altimmune, Inc. For: Jan 30 Filed by: Roberts M Scot

Form 8-K Altimmune, Inc. For: Feb 02

Form 4 Altimmune, Inc. For: Jan 30 Filed by: Garg Vipin K

Form 4 Altimmune, Inc. For: Jan 31 Filed by: Jordt Raymond M

Form SCHEDULE 13G/A Altimmune, Inc. Filed by: VANGUARD GROUP INC

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}